Pinnacle Wealth Management Advisory Group LLC Has $12.12 Million Position in Johnson & Johnson (NYSE:JNJ)

Pinnacle Wealth Management Advisory Group LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 83,802 shares of the company's stock after selling 2,099 shares during the period. Johnson & Johnson accounts for approximately 1.1% of Pinnacle Wealth Management Advisory Group LLC's portfolio, making the stock its 25th biggest position. Pinnacle Wealth Management Advisory Group LLC's holdings in Johnson & Johnson were worth $12,119,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. MOKAN Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $1,739,000. Blue Zone Wealth Advisors LLC raised its stake in Johnson & Johnson by 8.1% during the fourth quarter. Blue Zone Wealth Advisors LLC now owns 1,727 shares of the company's stock worth $250,000 after acquiring an additional 130 shares in the last quarter. Waypoint Wealth Partners Inc. boosted its holdings in shares of Johnson & Johnson by 43.3% in the 4th quarter. Waypoint Wealth Partners Inc. now owns 10,820 shares of the company's stock worth $1,565,000 after acquiring an additional 3,267 shares in the last quarter. Hourglass Capital LLC increased its position in Johnson & Johnson by 12.6% in the 4th quarter. Hourglass Capital LLC now owns 8,960 shares of the company's stock valued at $1,296,000 after acquiring an additional 1,000 shares in the last quarter. Finally, VeraBank N.A. lifted its stake in shares of Johnson & Johnson by 14.0% during the fourth quarter. VeraBank N.A. now owns 13,905 shares of the company's stock valued at $2,011,000 after acquiring an additional 1,705 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark A. Weinberger purchased 1,000 shares of the business's stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company's stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. Wolfe Research started coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price target on the stock. Argus upgraded Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Raymond James decreased their price target on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $170.67.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded up $3.71 during mid-day trading on Friday, hitting $163.39. 6,875,582 shares of the stock traded hands, compared to its average volume of 8,893,225. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The firm has a 50 day simple moving average of $148.61 and a two-hundred day simple moving average of $155.89. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a market cap of $393.37 billion, a PE ratio of 24.54, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business posted $2.29 earnings per share. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's payout ratio is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.